On the morning of July 16, the "Guidelines for Psoriasis Diagnosis and Treatment in China" (2022 Edition) was successfully held in Suzhou Dushu Lake World Hotel. The conference was hosted by the Psoriasis Specialty Committee of the Chinese Medical Association Dermatology and Venereology Branch, undertaken by the Dushu Lake Hospital Affiliated to Soochow University, and co-organized by the Dermatologist Branch of the Chinese Medical Doctor Association and the Dermatology and Skin Cosmetology Branch of the Chinese Medical Equipment Association. Zhonghao, Guangdong Supported by Pharmaceutical Co., Ltd., 31 editorial board members from all over the country participated in this seminar offline and online.

meeting venue

        Professor Zhang Furen from the Dermatology Hospital of Shandong First Medical University and Professor Wang Gang from Xijing Hospital of Air Force Military Medical University presided over the second half of the conference respectively. Chinese Medical Association Professor Zhang Xuejun, chairman of the Psoriasis Specialty Committee of the Dermatology Branch, gave a speech and shared the discussion and organization of this edition of the guide. Professor Zhang Xuejun pointed out that the current 2018 edition of "Guidelines for Diagnosis and Treatment of Psoriasis in China" has been published for nearly three years. Although dozens of interpretations of the guidelines for diagnosis and treatment of psoriasis have been held in China in the past three years, the coverage of the guideline is still not wide enough, especially For primary dermatologists. In the past three years, with the progress of basic and clinical research on psoriasis, new drugs for the treatment of psoriasis have continued to emerge. At present, patients' needs for skin lesions and quality of life have further increased. The 2018 version of the guidelines has been revised and improved in many aspects. space. Therefore, it is urgent to update and compile a more authoritative, instructive and practical diagnosis and treatment guide on the 2018 version of the "Guidelines for the Diagnosis and Treatment of Psoriasis in China".

Professor Zhang Xuejun gave a speech and shared the discussion and organization introduction of this edition of the guide

        Professor Zhang Xuejun then reviewed the compilation process of the 2018 version of the guide, from the current status of psoriasis diagnosis and treatment, psoriasis epidemiology, existing Chinese medicine and western psoriasis diagnosis and treatment Guidelines, existing problems in the development of the current diagnosis and treatment guidelines, the first drafting meeting of the 2018 version of the guidelines, mid-term discussion meetings, drafting and finalizing meetings, press conferences to the final publication of the guidelines and guidelines overview, etc. It also introduced the organization and organization of the "Guidelines for the Diagnosis and Treatment of Psoriasis in China" (2022 Edition), including the composition and members of the editorial board, and the preparation of a preliminary plan. It is planned to take one year to write and publish it, and it is planned to be completed in 2022. Released during the Sixth China Psoriasis Congress.

Chaired by Professor Zhang Furen and Professor Wang Gang

        On this editorial board, each editorial board issued their own suggestions for the compilation of the "Guidelines for the Diagnosis and Treatment of Psoriasis in China" (2022 Edition). The committee’s intense discussion led to a preliminary consensus as follows: 1. New psoriasis treatment drugs with evidence-based medical evidence can be written into the guidelines, and drugs that are not on the market but have batch numbers undergoing clinical drug trials can be written in an ambush pen. The included drugs are updated with reference to the latest high-quality literature and real-world data studies; 2. For traditionally used drugs (such as acitretin, methotrexate, and cyclosporine, etc.) Drugs need to increase the space, and there is a trade-off between the two. Drugs that are basically not used clinically (such as coal tar, leflunomide, etc.) are recommended to be mentioned in a generalized way to strengthen new drugs that are used more and have better efficacy. /Methods, weaken old drugs/methods that are used less frequently and have large side effects; 3. The evidence-based medicine of each drug recommends listing the level of evidence and further generalization; 4. The etiology and pathogenesis of psoriasis are not considered separately Part of it is written, and is included in the chronic disease management and prevention of psoriasis together with medical education, prevention, and psoriasis related questions and answers. It is written as a chapter; 5. For the part of psoriasis comorbidities and TCM diagnosis and treatment, it has Certain importance, and TCM has specific guidelines and consensus, the total length of this guide should not be too large, and mainstream diagnosis and treatment drugs/methods, etc., should not be long-formed; 6. The compilation of each part needs to find the highest evidence-based medicine basis Reference documents, check treatment, and case report documents need to be screened before being cited; 7. The content that is controversial is not included in the guide. Based on these principles, this editorial committee has initially determined the outline of the "Guidelines for the Diagnosis and Treatment of Psoriasis in China" (2022 Edition), including overview, diagnosis and classification of psoriasis, treatment of psoriasis, diagnosis of psoriasis by Chinese medicine, and Six chapters: treatment, chronic disease management and prevention, and international psoriasis professional organization.

The editorial board actively spoke and discussed intensely

        Finally, Professor Zhang Xuejun concluded that the compilation of the new version of the "Guidelines for the Diagnosis and Treatment of Psoriasis in China" should continue to integrate traditional Chinese and Western medicine and incorporate new drugs and methods. The committee divided into groups, compiled by level, strictly controlled references, and finally compiled a practical diagnosis and treatment guide that can closely follow and guide the clinic, which is of great significance for improving the level of diagnosis and treatment of psoriasis by dermatologists in my country.

Group photo of the editorial board

Photo: Zhu Zhengwei